D. Nakamura

Claim CLM-SEP-0241 · 71 M · 5-day LOS · POS 21 · billed charge $52,100
📄 Claim as submitted
Billed DRG
871
Sepsis w/o MV >96h — WITH MCC
Pays
$13,598
A41.59Other gram-negative sepsis (Klebsiella)PDX
N17.9Acute kidney injury, unspecifiedMCC
K83.09Cholangitis, unspecifiedCC
E11.9Type 2 diabetes mellitus w/o complicationsCC
RW 1.9425 × $7,000 base · FY2026 V43.0
🩺 Medical chart
CLM-SEP-0241-seed-record.txtocr complete
71 M with type 2 diabetes and recent ERCP for choledocholithiasis (2 weeks prior) presented with 2 days of worsening right upper quadrant pain, fever, and jaundice consistent with Charcot's triad. ED vitals: T 38.9°C, HR 112, BP 92/58, RR 20, SpO2 97% on room air. Lactate 3.1 mmol/L. Total bilirubin 4.2, direct bilirubin 3.1, ALP 340 U/L. WBC 18.4. Creatinine 2.1 mg/dL (documented baseline 0.8 from pre-procedure labs 2 weeks prior). Blood cultures ×2 — both positive for Klebsiella pneumoniae. Emergent ERCP with stone extraction and biliary stent placement day 1. IV piperacillin-tazobactam initiated, narrowed per sensitivities. Creatinine trended: 2.1 → 1.8 → 1.3 → 0.9. Urine output maintained >0.5 mL/kg/hr throughout. Assessment: Klebsiella pneumoniae sepsis secondary to acute obstructive cholangitis; acute kidney injury (KDIGO stage 2), resolved.
🤖 Agent analysis
💬 Follow-up questions
Ask any question about this analysis — coding logic, guideline rationale, documentation gaps, or what-if scenarios.
Rate basis (FY2026 / V43.0): DRG 871 RW 1.9425 (verified CMS); DRG 872 RW 1.0299 (verified CMS FY2024); base $7,000 blended IPPS rate. Validation logic grounded in ICD-10-CM Official Guidelines §I.C.1.d, AHA Coding Clinic, UHDDS, and Sepsis-3 (Singer et al., JAMA 2016). This tool surfaces a recommendation for a human auditor and does not auto-adjudicate.